A Randomized, Placebo-Controlled, Double-Blind Crossover Trial Assessing the Combination of Noradrenergic/Serotonergic Reuptake Inhibitor and an Antimuscarinic Agent for the Treatment of Obstructive Sleep Apnea

Thomson, Luke; Landry, Shane A.; Joosten, Simon A.; Wong, Ai‐Ming; Cheung, Tin K; Beatty, Caroline; Hamilton, G.; Edwards, Bradley A.

doi:10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4521

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, our group administered the same therapy to six patients for 1 week in an open-label pilot trial: the consistent reduction of AHI on atomoxetine as well as oxybutynin vs. baseline suggested that the effect of these drugs could last beyond the first night [76 & ]. Subsequently, Thomson et al [78] in Melbourne investigated if atomoxetine could be substituted with drugs with mixed profiles, including both noradrenergic and serotonergic properties such as milnacipran and duloxetine (combined with oxybutynin). The trial compared the combinations to placebo and to oxybutynin taken alone over one night of treatment.…”

Section: Pharmacological Interventionsmentioning

confidence: 99%

“…Subsequently, Thomson et al [78] in Melbourne investigated if atomoxetine could be substituted with drugs with mixed profiles, including both noradrenergic and serotonergic properties such as milnacipran and duloxetine (combined with oxybutynin). The trial compared the combinations to placebo and to oxybutynin taken alone over one night of treatment.…”

Section: Pharmacological Interventionsmentioning

confidence: 99%

See 1 more Smart Citation

Upper airway muscles: influence on obstructive sleep apnoea pathophysiology and pharmacological and technical treatment options

Perger

Taranto‐Montemurro

2021

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

Purpose of reviewObstructive sleep apnoea (OSA) is highly prevalent with numerous deleterious effects on neurocognitive and cardiovascular health. It is characterized by collapse of the upper airway during sleep, due to the decrease in both basal and compensatory UA muscle activities. However, the leading treatment, continuous positive airway pressure, is often poorly tolerated. This review presents latest works focusing on novel interventions targeting upper airway muscles to alleviate OSA severity.Recent findingsIn the last years, researchers have focused on the development of alternative treatment strategies targeting UA muscle activation, including pharmacological and nonpharmacological interventions.SummaryAmong the nonpharmacological treatments, hypoglossal nerve stimulation aims to increase upper airway muscle phasic activity during sleep through electrical stimulation, while myofunctional therapy improves the activity and coordination of upper airway dilator muscles.Regarding OSA pharmacotherapy, recent findings strongly suggest that selective norepinephrine reuptake inhibitors such as atomoxetine and reboxetine, when administered with antimuscarinics such as oxybutynin, can alleviate OSA in most patients increasing pharyngeal dilator muscles activity during sleep. New combinations of norepinephrine reuptake inhibitors and antimuscarinics have further been explored with variable success and animal models showed that leptin, thyrothropin releasing hormone analogues and gene therapy hold potential for the future of OSA pharmacotherapy.

show abstract

Section: Pharmacological Interventionsmentioning

confidence: 99%

Section: Pharmacological Interventionsmentioning

confidence: 99%